| Literature DB >> 1336771 |
F V Fossella1, R J Winn, P Y Holoye, B Hallinan, M N Raber, K Hoelzer, J A Young, J Readling, B Bowers, W K Hong.
Abstract
We treated 34 chemotherapy-naive patients with stage IIIb or IV non-small cell lung cancer with trimetrexate 150-200 mg/m2 intravenously over 30 minutes every two weeks. Six of 31 evaluable patients (19%) achieved a partial response. The major toxic effects from this regimen were myelosuppression, nausea/vomiting, and skin rash. We conclude that this well-tolerated schedule of trimetrexate has significant activity as a single agent against non-small cell lung cancer.Entities:
Mesh：
Substances：
Year: 1992 PMID： 1336771 DOI： 10.1007/bf00944191
Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850